Summary & Overview
HCPCS J7525: Tacrolimus, Parenteral, 5 mg
HCPCS Level II code J7525 identifies tacrolimus, parenteral, 5 mg — an injectable immunosuppressive medication used in transplant medicine and other immune-mediated conditions. Nationally, accurate coding for parenteral tacrolimus matters for clinical care coordination, claims adjudication, and pharmacy utilization oversight because dosing and route affect clinical monitoring and payer coverage decisions. Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what J7525 represents clinically and operationally, plus benchmarks and policy context relevant to coverage and billing for parenteral tacrolimus. The publication summarizes reimbursement benchmarking, common billing scenarios, and recent policy changes that affect parenteral immunosuppressant drugs at a national level. It also provides clinical context on typical sites of service and service type to assist coders and revenue staff in aligning claims with clinical documentation. Data not available in the input for specific payor rates, associated taxonomies, and ICD-10 pairings are noted where applicable.
Billing Code Overview
HCPCS Level II code J7525 represents Tacrolimus, parenteral, 5 mg. This code denotes a parenteral formulation of the immunosuppressant tacrolimus, typically administered by intravenous or intramuscular injection or infusion as part of therapeutic management.
Service Type: Parenteral drug administration
Typical Site of Service: Hospital outpatient department, ambulatory infusion center, or skilled nursing facility
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A 52-year-old kidney transplant recipient presents for post-operative inpatient management on the transplant service. The patient requires intravenous immunosuppression due to delayed gastrointestinal absorption of oral medications following an anastomotic complication and temporary ileus. The transplant pharmacist verifies the ordered parenteral tacrolimus dose and prepares compounding under sterile conditions. Nursing administers J7525 (Tacrolimus, parenteral, 5 mg) via slow IV infusion or per institutional protocol with continuous monitoring of blood pressure, renal function, and tacrolimus trough levels. Laboratory draws for tacrolimus trough concentration, serum creatinine, and electrolytes are scheduled prior to dose adjustments. Documentation includes indication (prevention of solid organ transplant rejection), dose, route, lot number, administration time, patient tolerance, and any modifier documenting unusual circumstances (for example, a medically necessary reason for outpatient administration in a non-typical site). Typical site of service is an inpatient hospital or ambulatory infusion center when oral administration is not feasible.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Professional component | When reporting a separately identifiable professional component of a service provided related to administration oversight (rarely used with J-codes). |